Drug Development
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Gain critical insights into global drug development trends, clinical trial advancements, regulatory hurdles, and R&D strategies for pharma investors and BD.
Showing 1–12 of 29 articles
Quick answer
NovaPharmaNews Drug Development hub for FDA covers 29 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Biotech’s coming of age: AI, capital efficiency and China reshape the field
Global hematology trials keep research patient-centered and regionally relevant
SGS Expands Bioanalytical Testing Capabilities in North America with Acquisition of CMIC, INC.
FDA Issues Final Guidance for Pulmonary Tuberculosis Drug Development
Kardigan's IPO Plans: Fueling the Next Wave of Cardiovascular Drug Development
ASCO 2026: Key Takeaways on Cancer Care Barriers and New Treatments
Palvella's Nasdaq Uplisting: Implications for Rare Disease Development
FDLI Annual 2026: Key Regulatory Updates and Industry Trends
FDLI Annual 2026: Key Regulatory Insights & Policy Updates
InflaRx Izicopan Shows Low Reactive Metabolite Formation in Liver Safety Study
InflaRx Reports Favorable Safety Profile for Izicopan in Liver Metabolism Study
ANVISA Clinical Trial Regulations: What Foreign Pharma Must Know in 2025
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.